Cargando…
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
BACKGROUND: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse event related to SU, reported as predictive factor in renal cel...
Autores principales: | Rutkowski, Piotr, Bylina, Elżbieta, Klimczak, Anna, Świtaj, Tomasz, Falkowski, Sławomir, Kroc, Jacek, Ługowska, Iwona, Brzeskwiniewicz, Magdalena, Melerowicz, Wojciech, Osuch, Czesław, Mierzejewska, Ewa, Wasielewski, Kacper, Woźniak, Agnieszka, Grzesiakowska, Urszula, Nowecki, Zbigniew I, Siedlecki, Janusz A, Limon, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361487/ https://www.ncbi.nlm.nih.gov/pubmed/22439647 http://dx.doi.org/10.1186/1471-2407-12-107 |
Ejemplares similares
-
The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017) -
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
por: Rutkowski, Piotr, et al.
Publicado: (2013) -
Treatment of Gastrointestinal Stromal Tumors (GISTs): A Focus on Younger Patients
por: Dudzisz-Śledź, Monika, et al.
Publicado: (2022) -
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011) -
Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)